Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsThe Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide AnalogsΜanagement of patients with hepatitis B and C before and after liver and kidney transplantationTenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patientsRisk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentPrevalence and factors associated with renal dysfunction among HIV-infected patientsImpact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.The New Epidemiology of HIV-Related Kidney Disease.Tenofovir disoproxil fumarate for the treatment of HIV infection.Recent developments in HIV-related kidney disease.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialGenetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionTenofovir-associated renal dysfunction in clinical practice: An observational cohort from western IndiaA consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factorsAn update on the use of Atripla in the treatment of HIV in the United States.Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort.Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.Tenofovir-induced kidney injury.Antiretroviral-treated HIV-infected women have similar long-term kidney function trajectories as HIV-uninfected women.Atriplatrade mark - HIV therapy in one pill."One pill, once daily": what clinicians need to know about Atriplatrade mark.Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study.Antiretroviral therapy-induced changes in plasma lipids and the risk of kidney dysfunction in HIV-infected menRenal function with use of a tenofovir-containing initial antiretroviral regimenTenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.Microalbuminuria in HIV disease.Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy.Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 InfectionRenal toxicity associated with tenofovir use.How to manage HIV-infected patients with chronic kidney disease in the HAART era.HIV therapies and the kidney: some good, some not so good?
P2860
Q24674939-D1529FB4-8D80-441A-AE5C-869117DB1284Q26781795-BBED71C5-950A-4C27-B8E5-F86A6AB28616Q26864647-8453C840-4B87-488C-8E1F-51F9E884D743Q26995852-324E059A-1242-482F-B122-147A63CCD19EQ27009523-59E8E4FA-0E93-4294-8EE3-076E5D5710FCQ28554081-CA4EAA0C-3404-419C-8BC2-5DFE31D81B6BQ30484533-BDFB2252-5A9A-4676-B506-B49D6B16DA4FQ31028855-0BC5B464-100E-4E17-8AB8-526F7E7EAAF2Q33820144-3FEDA37F-3D65-4B62-82F9-8F98A926DBE5Q34307868-EEFD3A71-E091-4384-A538-B1CF7B3BE689Q34569309-576A016D-A2DF-47DF-B9EC-54A95F759084Q34572458-9FADF7B5-FDFD-4C10-BEB3-783EC9F75CBAQ34952127-6AC5BB18-FECE-4BBC-8138-5AD1DE46A54FQ35016654-8112001E-29F5-435B-B9B1-D16B0412380CQ35117296-72F4B393-8D64-4B21-AE25-748ADCEDA6DEQ35149475-4E404537-E6EF-4F5E-B2B3-706CA7277254Q35206635-B135C8F3-EF72-4980-86D0-F58D71CAE406Q35557269-0C40933D-7315-48A6-B435-307C24E9979EQ36237157-BD075AB3-7569-4799-81D7-9ADB76251F63Q36407276-A66A6146-44F9-477B-991F-21D9CDE3A4E2Q36429743-15D2E6DC-6BC6-4835-8137-7D165ED83074Q36451062-325200FF-DB4B-4C24-9291-E7DEC1E945A9Q36576316-66842DE4-ECFE-4328-ABF8-AF990FC09054Q36607380-7213016A-A295-4B82-8816-C9B7A5B7BE3AQ36723349-962D597E-FCBE-47A9-BA13-DC650861AFE4Q36762441-7A213033-31B5-44CD-815E-75396612F360Q36795839-DFA6E96F-0CE2-4E5D-A0C8-B23AF4D0DE05Q36818184-A0894772-6FDB-4905-8180-74C320A37CECQ36823570-37D64879-1188-4C7A-A2DF-8DEEA67677B6Q36870864-48201832-B83E-44AA-8DFD-B5EC2E058395Q36910943-E7E99EB0-E205-4310-9A93-A5B3FF620AB5Q37204118-C53F825A-4B8B-4A85-8AF2-5264B920E357Q37215065-66D53C9F-CAA5-4987-AD34-FC460B4563CCQ37238911-98517902-4D8C-406F-A01B-41062D8F63EAQ37259613-E6B3DC0D-A69D-4BE7-A653-84E989365DA5Q37505250-B894F575-1132-4D27-90B8-D7448BE95FAAQ37705969-60882177-7F0A-488D-97FE-A790FE39BB92Q37729160-2E982997-8C0A-4BB9-92E5-009D3E175484Q37980388-4FE0C85A-18DE-46E8-9D0A-8296EC2A59FDQ37988776-F018C39E-9E33-4C7C-83ED-703B8CEA47FE
P2860
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Long-term renal safety of teno ...... -controlled multicentre study.
@ast
Long-term renal safety of teno ...... -controlled multicentre study.
@en
type
label
Long-term renal safety of teno ...... -controlled multicentre study.
@ast
Long-term renal safety of teno ...... -controlled multicentre study.
@en
prefLabel
Long-term renal safety of teno ...... -controlled multicentre study.
@ast
Long-term renal safety of teno ...... -controlled multicentre study.
@en
P2093
P2860
P356
P1476
Long-term renal safety of teno ...... -controlled multicentre study.
@en
P2093
Andrew Cheng
Daniel Vittecoq
Gilbert Deray
Hassane Izzedine
Jean Sebastien Hulot
Joel E Gallant
Schlomo Staszewski
Study 903 Team
P2860
P304
P356
10.1093/NDT/GFH658
P407
P577
2005-03-01T00:00:00Z